Veea (VEEA) surged 67% amid heavy trading after the company said late Thursday it regained full compliance with Nasdaq's continued listing requirements.

More than 68 million shares traded intraday, compared with a daily average of about 6.7 million.

Humana (HUM) affirmed its full-year 2026 guidance of at least $9 in adjusted earnings per common share on Friday. Oppenheimer raised Humana's price target to $475 from $405 while maintaining its outperform rating.

Shares jumped 13%, with intraday trading volume rising to over 2.8 million, versus a daily average of about 1.3 million.

Moderna (MRNA) and other vaccine developers' shares rose after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate cancer vaccines' development.

Shares climbed 9%, with intraday trading volume at over 15 million, versus a daily average of roughly 18 million.

Price: 6.46, Change: +2.59, Percent Change: +66.93